EpiAirway’s Air-liquid interface (ALI) format provides a physiologically relevant model for inhaled chemicals including vapors, gases and (nano)particles. Use EpiAirway to determine relative toxicity of environmental and occupational pollutants, and the relative safety of inhaled drug formulations, tobacco and e-cigarette products.
EpiAirway tissues (Figure 1) are equilibrated overnight under standard culture conditions (37°C, 5% CO2) with EpiAirway Assay Media (AIR-100-ASY). 18-24 hours later the apical surface of the tissue is washed twice by adding 400 μl DPBS into the culture insert and carefully aspirating to remove all liquid. Culture supernatants are aspirated and replaced with fresh, pre-warmed media. EpiAirway is exposed to test material. Following exposure, test material is rinsed from the tissue with PBS and tissue viability is determined by the MTT assay.
EpiAirway is used across a wide range of industries for the determination of inhalation toxicity to occupational chemicals, environmental aggressors, nanoparticles, tobacco (whole smoke and its constituents), active pharmaceutical ingredients and inhalation formulations. Mechanisms of injury and repair following exposure to toxic materials can also be studied with the EpiAirway tissue model.
EpiAirway’s in vivo-like barrier properties, mucociliary differentiation, drug transporters and drug metabolism enzymes make EpiAirway ideal for the rapid and cost-effective preclinical evaluation of inhalation toxicity.